logo
logo
Sign in

Opioid-Induced Constipation Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

avatar
Ankit Nigam
Opioid-Induced Constipation Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

Opioid-Induced Constipation Market Analysis, Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

 

(Albany, US) DelveInsight has launched a new report on "Opioid-Induced Constipation - Market Insights, Epidemiology, and Market Forecast-2030".

DelveInsight's "Opioid-Induced Constipation - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Opioid-Induced Constipation, historical and forecasted epidemiology as well as the Opioid-Induced Constipation market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Companies covered:

  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Daiichi Sankyo Co. Ltd.
  • Ironwood Pharmaceuticals Inc.
  • Mallinckrodt Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • SHIONOGI Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd

View Report: https://www.delveinsight.com/report-store/opioid-induced-constipation-market

Request free Sample: https://www.delveinsight.com/report-store/opioid-induced-constipation-market

Opioid-Induced Constipation Epidemiology  

The Opioid-Induced Constipation epidemiology division provide insights about historical and current Opioid-Induced Constipation patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Scope of the Report

  • The report covers the descriptive overview of Opioid-Induced Constipation, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Opioid-Induced Constipation epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Opioid-Induced Constipation are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Opioid-Induced Constipation market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Opioid-Induced Constipation market

 

View Report: https://www.delveinsight.com/report-store/opioid-induced-constipation-market

Request free Sample: https://www.delveinsight.com/report-store/opioid-induced-constipation-market

 

Opioid-induced constipation (OIC) is the most common side effect of opioid therapy because of the distribution of opioid receptors throughout the GI tract. Although OTC treatment for OIC is common, patients with more-severe symptoms often move to prescription drug therapy. The OIC drug market includes FDA-approved mu opioid receptor antagonists: Shionogi’s Symproic, Salix’s Relistor, and AstraZeneca / Daiichi Sankyo’s Movantik. Other therapies with alternative MOAs approved or in late-phase development include Allergan / Ironwood’s Linzess, a guanylate cyclase-C agonist; Mallinckrodt’s Amitiza, a bicyclic fatty acid; and Takeda’s Motegrity, a 5-HT4-receptor agonist. Given the number of agents now available / in development for OIC, understanding how and where each is positioned in the treatment algorithm is increasingly important as developers work to differentiate their product from the competition.


 

Opioid-Induced Constipation Market Outlook

The Opioid-Induced Constipation market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Opioid-Induced Constipation market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

This segment gives a thorough detail of Opioid-Induced Constipation market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

According to DelveInsight, Opioid-Induced Constipation market in 7MM is expected to change in the study period 2017-2030.

View Report: https://www.delveinsight.com/report-store/opioid-induced-constipation-market

Request free Sample: https://www.delveinsight.com/report-store/opioid-induced-constipation-market

 

Table of Contents:

  1. Key Insights
  2. Executive Summary of Opioid-Induced Constipation
  3. Competitive Intelligence Analysis for Opioid-Induced Constipation
  4. Opioid-Induced Constipation: Market Overview at a Glance

4.1. Opioid-Induced Constipation Total Market Share (%) Distribution in 2017

4.2. Opioid-Induced Constipation Total Market Share (%) Distribution in 2030

  1. Opioid-Induced Constipation: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

  1. Patient Journey
  2. Opioid-Induced Constipation Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Opioid-Induced Constipation Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Opioid-Induced Constipation Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Opioid-Induced Constipation Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Opioid-Induced Constipation Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Opioid-Induced Constipation Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Opioid-Induced Constipation Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Opioid-Induced Constipation Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Opioid-Induced Constipation Epidemiology Scenario in Japan (2017-2030)

  1. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Opioid-Induced Constipation Treatment and Management

8.2. Opioid-Induced Constipation Treatment Algorithm 

  1. Unmet Needs
  2. Key Endpoints of Opioid-Induced Constipation Treatment
  3. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

  1. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

  1. Opioid-Induced Constipation: Seven Major Market Analysis

13.1. Key Findings

13.2. Opioid-Induced Constipation Market Size in 7MM

13.3. Opioid-Induced Constipation Market Size by Therapies in the 7MM

  1. Attribute analysis
  2. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Opioid-Induced Constipation Total Market Size in the United States

15.1.2. Opioid-Induced Constipation Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Opioid-Induced Constipation Total Market Size in Germany

15.3.2. Opioid-Induced Constipation Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Opioid-Induced Constipation Total Market Size in France

15.4.2. Opioid-Induced Constipation Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Opioid-Induced Constipation Total Market Size in Italy

15.5.2. Opioid-Induced Constipation Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Opioid-Induced Constipation Total Market Size in Spain

15.6.2. Opioid-Induced Constipation Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Opioid-Induced Constipation Total Market Size in the United Kingdom

15.7.2. Opioid-Induced Constipation Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Opioid-Induced Constipation Total Market Size in Japan

15.8.3. Opioid-Induced Constipation Market Size by Therapies in Japan

  1. Access and Reimbursement Overview of Opioid-Induced Constipation
  2. KOL Views
  3. Market Drivers
  4. Market Barriers
  5. Appendix

20.1. Bibliography

20.2. Report Methodology

  1. DelveInsight Capabilities
  2. Disclaimer
  3. About DelveInsight

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for

Browse through our vast repository from here.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: [email protected]
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

collect
0
avatar
Ankit Nigam
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more